Benzodiazepine Classification and Clinical Use

Pharmacological Properties

Benzodiazepines activate GABA-A receptors in the brain, enhancing inhibitory neurotransmission, and have anxiolytic, amnestic, sedating, hypnotic, and anticonvulsant effects 1, 2
All benzodiazepines are metabolized by the liver, with clearance reduced in hepatic dysfunction 3
Lipid solubility affects onset of action: midazolam and diazepam (more lipid soluble) have quicker onset than lorazepam 1

Short-acting benzodiazepines, such as midazolam, have a half-life of 1.8-3.1 hours, rapid onset, and short duration, making them suitable for procedural sedation 1
Intermediate-acting benzodiazepines, such as lorazepam, have a half-life of 8-15 hours, onset within 15-20 minutes, and no active metabolites, making them safer in renal impairment 1, 3
Long-acting benzodiazepines, such as diazepam, have a half-life of 20-120 hours, rapid onset, but prolonged effect due to active metabolites, and may accumulate with repeated dosing, especially in renal dysfunction 1, 3

Elderly patients are significantly more sensitive to sedative effects of benzodiazepines 1
Benzodiazepines can cause respiratory depression when used, and elderly patients are at higher risk of falls and cognitive impairment, requiring lower doses 4
In patients with hepatic dysfunction, reduced clearance of benzodiazepines requires dose adjustment 3
In patients with renal impairment, active metabolites of midazolam and diazepam may accumulate 3

Lorazepam is often preferred for acute agitation and chemical restraint due to its rapid and complete absorption with no active metabolites 2
Midazolam has a more rapid onset but shorter duration, making it suitable for procedural sedation 2
Benzodiazepines, such as lorazepam or midazolam, can be used for dyspnea in advanced cancer, especially when anxiety is present 5

Benzodiazepines carry no cardiac arrhythmia risk and do not prolong QT interval, making them safe from a cardiovascular standpoint for patients with palpitations 6
In vitro studies show both inhibition and activation of potassium currents, but no QT changes occur in clinical use 6
However, benzodiazepines cause drowsiness, cognitive deficits, and are an independent risk factor for falls, especially in elderly patients 7